Go Pro

Malcolm Hoffman Analyst Performance

Analyst at BMO Capital Markets

Malcolm Hoffman is a stock analyst at BMO Capital Markets in the healthcare sector, covering 3 publicly traded companies. Over the past year, Malcolm Hoffman has issued 7 stock ratings, including strong buy and buy recommendations. While full access to Malcolm Hoffman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Malcolm Hoffman's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
7 Last 0 Years
Buy Recommendations
100.00% 7 Buy Ratings
Companies Covered
3 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy42.9%3 ratings
Buy57.1%4 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

Out of 7 total stock ratings issued by Malcolm Hoffman at BMO Capital Markets, the majority (57.1%) have been Buy recommendations, followed by 42.9% Strong Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
3 companies

Malcolm Hoffman, an analyst at BMO Capital Markets, currently covers 3 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
3 companies
100.0%

Malcolm Hoffman of BMO Capital Markets specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
PHARMACEUTICALS
2 companies
66.7%
BIOTECHNOLOGY
1 company
33.3%

Malcolm Hoffman's Ratings History at BMO Capital Markets

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
LB Pharmaceuticals Inc stock logo
LBRX
LB Pharmaceuticals
8/12/2026Boost Price Target$45.33$54.00Outperform
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
7/20/2026Initiated Coverage$221.64$310.00Outperform
Maplight Therapeutics, Inc. stock logo
MPLT
Maplight Therapeutics
7/20/2026Initiated Coverage$35.99$46.00Outperform
LB Pharmaceuticals Inc stock logo
LBRX
LB Pharmaceuticals
7/20/2026Initiated Coverage$30.90$46.00Outperform
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
7/20/2026Upgrade$236.95Strong-Buy
LB Pharmaceuticals Inc stock logo
LBRX
LB Pharmaceuticals
7/20/2026Upgrade$32.31Strong-Buy
Maplight Therapeutics, Inc. stock logo
MPLT
Maplight Therapeutics
7/20/2026Upgrade$37.44Strong-Buy